brobert
/
LogseqFMS
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity

Auto saved by Logseq

Browse Source
master
FMS 9 months ago
parent e3a1da83e5
commit 9076df5ea0
2 changed files with 6 additions and 2 deletions
Show Stats Download Patch File Download Diff File

3
pages/STOP2030___STAB.md
Unescape Escape View File

@ -24,4 +24,5 @@ alias:: STOP2030/Advisory Board
- We're establishing internal communication channels that keep all partners engaged with the project and updated. - We're establishing internal communication channels that keep all partners engaged with the project and updated.
- We're planning a media training course to be delivered to all partners - We're planning a media training course to be delivered to all partners
- -
- -
-

5
pages/STOP2030___Web___Posts.md
Unescape Escape View File

@ -1,6 +1,7 @@
# [[WHO]] visit # [[WHO]] visit
- -
- # REALISE study registration - # REALISE study registration
collapsed:: true
- ## The design of our REALISE study is now complete, and published - ## The design of our REALISE study is now complete, and published
- #+BEGIN_VERSE - #+BEGIN_VERSE
At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial. At STOP2030 we want to provide a pharmacological tool that helps at delivering WHO's elimination goals for soil-transmitted helminthiasis (STH). We are happy to announce that we've completed the design of the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our largest clinical trial.
@ -30,4 +31,6 @@
The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, serving as an active control group, will receive a single dose of albendazole 400mg, the current standard. The clinical trial will have two arms, randomized by school. One arm will receive a single dose of the fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and 14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm, serving as an active control group, will receive a single dose of albendazole 400mg, the current standard.
If you want to review the full protocol, please visit the REALISE study's page on clinicaltrials.gov or PACTR (trial id: PACTR202402529220760). If you want to review the full protocol, please visit the REALISE study's page on clinicaltrials.gov or PACTR (trial id: PACTR202402529220760).
#+END_VERSE #+END_VERSE
- # First STAB meeting
- ## Our project start
Write Preview
Loading…
Cancel
Save